

Overview

Useful For

Evaluation of pediatric bone marrow and peripheral blood specimens by fluorescence in situ hybridization probe analysis for classic rearrangements and chromosomal copy number changes associated with B-cell acute lymphoblastic leukemia/lymphoma (B-ALL) and Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) in patients being considered for enrollment in Children's Oncology Group (COG) clinical trials and research protocols

As an adjunct to conventional chromosome studies in performed in pediatric patients with B-ALL and Ph-like ALL being considered for enrollment in COG protocols

Reflex Tests

| Test Id | Reporting Name | Available Separately | Always Performed |
|---------|--------------------------------|----------------------|------------------|
| COGBB | Probe, Each Additional (COGBF) | No, (Bill Only) | No |

Testing Algorithm

[This test is only performed on specimens from pediatric patients being considered for enrollment in a Children's Oncology Group \(COG\) protocol.](#)

The FISH panel includes testing for the following abnormalities using the fluorescence in situ hybridization (FISH) probes listed:

- +9/9p-, CDKN2A/D9Z1
- t(9;22) BCR/ABL1
- 11q23 rearrangement, MLL (KMT2A) break-apart
- 17/17p-, TP53/D17Z1
- t(1;19)(q23;p13), PBX1/TCF3
- Hyperdiploidy, +4,+10,+17: D4Z1/D10Z1/D17Z1
- t(12;21)(p13;q22), ETV6/RUNX1 fusion and iAMP21
- 14q32 rearrangement, IGH break-apart
- t(Xp22.33;var) or t(Yp11.32;var), P2RY8 rearrangement
- t(Xp22.33;var) or t(Yp11.32;var), CRLF2 rearrangement
- 8q24.1 rearrangement, MYC break-apart

If the FISH panel demonstrates normal or nonclassical abnormalities, BALPF / B-Cell Acute Lymphoblastic Leukemia/Lymphoma (ALL), FISH, Pediatric Varies panel will be performed.

The Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) panel includes testing for the following

kinase activating chromosome abnormalities, using the FISH probes listed below as well as *IKZF1* deletion, which often accompanies Ph-like ALL:

1q25 rearrangement, ABL2 break-apart
5q32 rearrangement, PDGFRB break-apart
9p24.1 rearrangement, JAK2 break-apart
9q34 rearrangement, ABL1 break-apart
7p-, IKZF1/CEP7

When an MLL (KMT2A) rearrangement is identified, reflex testing will be performed to identify the translocation partner. Probes include identification of:

t(4;11)(q21;q23) AFF1/MLL
t(6;11)(q27;q23) MLLT4(AFDN)/MLL
t(9;11)(p22;q23) MLLT3/MLL
t(10;11)(p12;q23) MLLT10/MLL
t(11;19)(q23;p13.1) MLL/ELL
t(11;19)(q23;p13.3) MLL/MLLT1

[When an IGH and/or CRLF2 rearrangement is identified, reflex testing will be performed using the CRLF2/IGH fusion probe set to identify a potential t\(X;14\)\(p22.33;q32\) or t\(Y;14\)\(p11.32;q32\) cryptic translocation.](#)

In the absence of BCR/ABL1 fusion, when an extra ABL1 signal is identified, reflex testing will be performed using the ABL1 break-apart probe set to evaluate for the presence or absence of an *ABL1* rearrangement.

[In the absence of ETV6/RUNX1 fusion, when an extra ETV6 signal is identified, reflex testing will be performed using the ETV6 break-apart probe set to evaluate for the presence or absence of an *ETV6* rearrangement.](#)

If a MYC rearrangement is identified, both the BCL2 and BCL6 probe sets will be performed.

Method Name

Fluorescence In Situ Hybridization (FISH)

NY State Available

Yes

Specimen

Specimen Type

Varies

Ordering Guidance

B-Cell Acute Lymphoblastic
Leukemia/Lymphoma (ALL), Children's
Oncology Group Enrollment Testing, FISH,
Varies

[This test is only performed on specimens from pediatric patients being considered for enrollment in a Children's Oncology Group \(COG\) protocol. If this test is ordered and the laboratory is informed that the patient is not on a COG protocol, this test will be canceled and automatically reordered by the laboratory as BALPF / B-Cell Acute Lymphoblastic Leukemia/Lymphoma \(ALL\), FISH, Pediatric Varies.](#)

At follow-up, conventional cytogenetic studies (CHRBM / Chromosome Analysis, Hematologic Disorders, Bone Marrow) and targeted B-cell ALL [fluorescence in situ hybridization](#) (FISH) probes can be evaluated based on the abnormalities identified in the diagnostic study. Order BALMF / B-Cell Acute Lymphoblastic Leukemia/Lymphoma (ALL), Specified FISH, Varies and request specific probes or abnormalities.

Shipping Instructions

Advise Express Mail or equivalent if not on courier service.

Necessary Information

1. A reason for testing, a flow cytometry and/or a bone marrow pathology report, and a Children's Oncology Group (COG) registration number and protocol number should be submitted with each specimen. The laboratory will not reject testing if this information is not provided; however, appropriate testing and interpretation may be compromised or delayed. [If not provided, an appropriate indication for testing may be entered by Mayo Clinic Laboratories.](#)
2. If a patient has received an opposite sex bone marrow transplant prior to specimen collection for this protocol, note this information on the request.

Specimen Required

Submit only 1 of the following specimens:

Preferred:

Specimen Type: Bone marrow

Container/Tube:

Preferred: Yellow top (ACD)

Acceptable: Green top (heparin) or lavender top (EDTA)

Specimen Volume: 2 to 3 mL

Collection Instructions:

1. **It is preferable to send the first aspirate from the bone marrow collection.**
2. Invert several times to mix bone marrow.
3. Send bone marrow specimen in original tube. **Do not aliquot.**

Acceptable:

Specimen Type: Blood

Container/Tube:

Preferred: Yellow top (ACD)

Acceptable: Green top (heparin) or lavender top (EDTA)

Specimen Volume: 6 mL

Collection Instructions:

1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. **Do not aliquot.**

Forms

If not ordering electronically, complete, print, and send a [Children's Oncology Group Test Request \(T829\)](#) with the specimen.

Specimen Minimum Volume

Blood: 2 mL

Bone Marrow: 1 mL

Reject Due To

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Specimen Stability Information

| Specimen Type | Temperature | Time | Special Container |
|---------------|---------------------|------|-------------------|
| Varies | Ambient (preferred) | | |
| | Refrigerated | | |

Clinical & Interpretive

Clinical Information

In the United States, the incidence of acute lymphoblastic leukemia (ALL) is roughly 6000 new cases per year (as of 2019). ALL accounts for approximately 70% of all childhood leukemia cases (ages 0-19 years), making it the most common type of childhood cancer. Approximately 85% of pediatric cases of ALL are B-cell lineage (B-ALL) and 15% are T-cell lineage (T-ALL). It has a peak incidence at 2 to 5 years of age. The incidence decreases with increasing age, before increasing again at around 50 years of age. ALL is slightly more common in male patients than female patients. There is an increased incidence of ALL in individuals with Down syndrome, Fanconi anemia, Bloom syndrome, ataxia telangiectasia, X-linked agammaglobulinemia, and severe combined immunodeficiency. The overall cure rate for ALL in children is about 90% and about 45% to 60% of adults have long-term disease-free survival. *CRLF2/IGH* rearrangements are more commonly observed in patients with Down syndrome or of Hispanic descent.

Specific genetic abnormalities are identified in the majority of cases of B-ALL, either by conventional chromosome studies or fluorescence in situ hybridization (FISH) studies. For more than 25 years, the Mayo Clinic Genomics Laboratory has served as a Children's Oncology Group (COG) accredited laboratory for the performance of cytogenetic testing in pediatric patients being considered for enrollment in COG clinical trials and research. The laboratory is highly equipped to perform the time sensitive and critical cytogenetic testing necessary to assign risk stratification and facilitate enrollment in COG protocols.

Each of the B-ALL genetic subgroups is important to detect and can be critical prognostic markers. The decision for early

transplantation may be made if t(9;22)(q34;q11.2), *MLL (KMT2A)* translocations, *RUNX1* duplication/amplification (iAMP21) or a hypodiploid clone is identified. In contrast, if the *ETV6/RUNX1* fusion is detected by FISH or hyperdiploidy is identified by chromosome studies, the patient has a favorable prognosis and transplantation is rarely considered.

A newly recognized World Health Organization entity *BCR-ABL1*-like ALL, also known as Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL), is increasing in importance due to the poor prognosis seen in pediatric, adolescent, and young adult ALL. Common features of this entity involve rearrangements with tyrosine kinase genes involving the following genes: *ABL2*, *PDGFRB*, *JAK2*, *ABL1*, *CRLF2*, and *P2RY8*. [Deletion of *IKZF1* often accompanies this entity. Some patients who have failed conventional therapies have demonstrated favorable responses to targeted therapies in clinical trials when rearrangements involving these specific gene regions have been identified.](#)

Evaluation of the *MYC* gene region is included in all diagnostic B-ALL panels to evaluate for Burkitt lymphoma. If a positive result is obtained, additional testing for the *BCL2* and *BCL6* gene regions will be performed.

[Metaphase FISH confirmation of classic translocations that are cryptic and not visually detectable by chromosome analysis \[ie, t\(12;21\) associated with *ETV6/RUNX1* fusion\] is performed, as required by COG, and is included as part of the electronic case submission by the Mayo Clinic Genomics Laboratory to COG for central review.](#)

Additional cytogenetic techniques such as chromosomal microarray (CMAH / Chromosomal Microarray, Hematologic Disorders, Varies) may be helpful to resolve questions related to ploidy (hyperdiploid clone vs doubled hypodiploid clone) or to resolve certain clonal structural rearrangements such as the presence or absence of intra-chromosomal amplification of chromosome 21 (iAMP21). A summary of the characteristic chromosome abnormalities identified in B-ALL is listed in the following table.

Table. **Common Chromosome Abnormalities in B-cell Acute Lymphoblastic Leukemia**

| Leukemia type | Cytogenetic change | Typical demographic | Risk category |
|-------------------------------------|---|---------------------|---------------|
| B-cell acute lymphoblastic leukemia | t(12;21)(p13;q22), <i>ETV6(TEL)/RUNX1(AML1)</i> | Pediatric | Favorable |
| | Hyperdiploidy | Pediatric | Favorable |
| | t(1;19)(q23;p13.3), <i>PBX1/TCF3</i> | Pediatric | Intermediate |
| | t(9;22)(q34;q11.2), <i>BCR/ABL1</i> | Pediatric/adult | Unfavorable |
| | iAMP21, <i>RUNX1</i> | Pediatric | Unfavorable |
| | del(9p), <i>CDKN2A(p16)</i> | All ages | Unknown |
| | t(11q23;var), <i>MLL</i> | All ages | Unfavorable |
| | t(4;11)(q21;q23), <i>AFF1(AF4)/MLL</i> | All ages | Unfavorable |
| | t(6;11)(q27;q23), <i>MLLT4(AFDN)/MLL</i> | All ages | Unfavorable |
| | t(9;11)(p22;q23), <i>MLLT3(AF9)/MLL</i> | All ages | Unfavorable |
| | t(10;11)(p12;q23), <i>MLLT10/MLL</i> | All ages | Unfavorable |
| | t(11;19)(q23;p13.1), <i>MLL/ELL</i> | All ages | Unfavorable |

| | | | |
|--|--|--|--|
| | t(11;19)(q23;p13.3), <i>MLL/MLLT1(ENL)</i> | All ages | Unfavorable |
| | t(14q32;var), <i>IGH</i> | All ages | Variable |
| | t(X;14)(p22;q32)/t(Y;14)(p11;q32), <i>CRLF2/IGH</i> | Adolescent/young adult | Unfavorable |
| | t(Xp22.33;var) or t(Yp11.32;var), <i>CRLF2</i> | All ages | Unfavorable |
| | t(Xp22.3;var) or t(Yp11.32;var), <i>P2RY8</i> | All ages | Unfavorable |
| | -17/17p-, <i>TP53</i> | All ages | Unfavorable |
| | t(8q24.1;var), <i>MYC</i> | Pediatric/ adolescent/ young adult | |
| | Complex karyotype (> or =4 abnormalities) | Adult | Unfavorable |
| | Low hypodiploidy/near triploidy | Adult | Unfavorable |
| | Near-haploid/hypodiploid | All ages | Unfavorable |
| | 7p-, <i>IKZF1</i> | All ages | Unfavorable in absence of ERG deletion |
| Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) | t(1q25;var), <i>ABL2</i> | Pediatric/ adolescent/ young adult | Unfavorable |
| | t(5q32;var), <i>PDGFRB</i> | | |
| | t(9p24.1;var), <i>JAK2</i> | | |
| | t(9q34;var), <i>ABL1</i> | | |
| | t(Xp22.33;var) or t(Yp11.32;var), <i>CRLF2</i> | | |
| | t(Xp22.33;var) or t(Yp11.32;var), <i>P2RY8</i> | | |

Reference Values

An interpretive report will be provided.

Interpretation

A neoplastic clone is detected when the percent of cells with an abnormality exceeds the normal reference range for any given probe.

The absence of an abnormal clone does not rule out the presence of a neoplastic disorder.

Cautions

This test is not approved by the US Food and Drug Administration, and it is best used as an adjunct to clinical and pathologic information.

Fluorescence in situ hybridization (FISH) is not a substitute for conventional chromosome studies because the latter detects chromosome abnormalities associated with other hematological disorders that would be missed by this FISH

panel test.

Bone marrow is the preferred specimen type for this FISH test. If bone marrow is not available, a blood specimen may be used if there are malignant cells in the blood specimen (as verified by a hematopathologist).

Supportive Data

Each probe was independently tested and verified on unstimulated peripheral blood and bone marrow specimens. Normal cutoffs were calculated based on the results of 25 normal specimens. For each probe set a series of chromosomally abnormal specimens was evaluated to confirm each probe set detected the abnormality it was designed to detect.

Clinical Reference

1. Moorman AV, Harrison CJ, Buck GAN, et al: Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. *Blood*. 2007 Apr 15;109(8):3189-3197
2. Moorman AV: The clinical relevance of chromosomal and genetic abnormalities in B-cell precursor acute lymphoblastic leukemia. *Blood Rev*. 2012 May;26(3):123-135
3. Roberts KG, Li Y, Payne-Turner D, et al: Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. *N Engl J Med*. 2014 Sep 11;371(11):1005-1015
4. Mullighan CG: The genomic landscape of acute lymphoblastic leukemia in children and young adults. *Hematology Am Soc Hematol Educ Program*. 2014 Dec 5;2014(1):174-180. doi: 10.1182/asheducation-2014.1.174
5. Swerdlow SH, Campo E, Harris NL, et al, eds: WHO Classification of Tumours. Vol 2. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. IARC Press; 2017

Performance

Method Description

[This test is performed using commercially available and laboratory-developed](#) probes. Deletion of the *CDKN2A* locus on chromosome 9, *TP53* on chromosome 17, deletion of *IKZF1* on chromosome 7, and gain of chromosomes 4, 10, and 17 are detected using enumeration strategy probes. Rearrangements involving *ABL2*, *PDGFRB*, *MYC*, *JAK2*, *ABL1*, *MLL*, *ETV6*, *IGH*, *MYC*, *CRLF2* and *P2RY8* are detected using a dual-color break-apart (BAP) strategy probe. Dual-color, dual-fusion fluorescence in situ hybridization (D-FISH) strategy probe sets are used to detect t(X/Y;14), t(9;22), t(12;21), t(1;19), and in reflex testing when rearrangements of the *MLL* gene is detected. If a *MYC* gene region separation is identified, break-apart *BCL2* and *BCL6* will be evaluated using a dual-color break-apart (BAP) strategy probe. For enumeration and BAP strategy probe sets, 100 interphase nuclei are scored; 200 interphase nuclei are scored when D-FISH probes are used. Results are expressed as the percent abnormal nuclei.(Unpublished Mayo method)

PDF Report

No

Test Definition: COGBF

B-Cell Acute Lymphoblastic
Leukemia/Lymphoma (ALL), Children's
Oncology Group Enrollment Testing, FISH,
Varies

Day(s) Performed

Monday through Friday

Report Available

7 to 10 days

Specimen Retention Time

4 weeks

Performing Laboratory Location

Rochester

Fees & Codes

Fees

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

Test Classification

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

88271 x 2, 88275, 88291-FISH Probe, Analysis, Interpretation; 1 probe set
88271 x 2, 88275-FISH Probe, Analysis; each additional probe set (if appropriate)

LOINC® Information

| Test ID | Test Order Name | Order LOINC® Value |
|---------|-------------------------|--------------------|
| COGBF | COG, ALL (B-cell), FISH | In Process |

| Result ID | Test Result Name | Result LOINC® Value |
|-----------|---------------------|---------------------|
| 602296 | Result Summary | 50397-9 |
| 602297 | Interpretation | 69965-2 |
| 602298 | Result Table | 93356-4 |
| 602299 | Result | 62356-1 |
| GC019 | Reason for Referral | 42349-1 |
| GC020 | Specimen | 31208-2 |
| 602301 | Source | 31208-2 |

Test Definition: COGBF

B-Cell Acute Lymphoblastic
Leukemia/Lymphoma (ALL), Children's
Oncology Group Enrollment Testing, FISH,
Varies

| | | |
|--------|------------------------|---------|
| 602302 | Method | 85069-3 |
| 602303 | Additional Information | 48767-8 |
| 602304 | Disclaimer | 62364-5 |
| 602305 | Released By | 18771-6 |